Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

 -Synuclein in Parkinson's Disease

(2013) L. Stefanis   Cold Spring Harbor Perspectives in Medicine

Neuroaxonal Regeneration is More Pronounced in Early Multiple Sclerosis than in Traumatic Brain Injury Lesions

(2012) Lucas Schirmer et al.   BRAIN PATHOLOGY

Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

(2011) Henrik Gensicke et al.   CNS DRUGS

Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis

(2011) Ruth Huizinga et al.   GLIA

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

(2011) J. Kuhle et al.   NEUROLOGY

Increased Intrathecal High-Avidity Anti-Tau Antibodies in Patients with Multiple Sclerosis

(2011) Lenka Fialová et al.   PLoS One

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Inflammation in neurodegenerative diseases

(2010) Sandra Amor et al.   IMMUNOLOGY

A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect

(2010) Ching-Hua Lu et al.   JOURNAL OF NEUROSCIENCE METHODS

Review: Natalizumab in the treatment of multiple sclerosis

(2009) Özgür Yaldizli et al.   Therapeutic Advances in Neurological Disorders

Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology

(2008) Axel Petzold et al.   EXPERIMENTAL NEUROLOGY

Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

(2008) Hayrettin Tumani et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS